According to RNC Pharma data, nearly 12,900 unique SKUs (stock keeping units) of medicines were introduced, representing an increase of 322 items compared to the same period in 2024. The number of trademarks (TM) and international nonproprietary names (INN) also saw growth. Specifically, 4,300 trademarks entered circulation in 2025—73 more than the previous year.
Among the new product launches is Meronem (meropenem) from Altegra, which debuted in February 2025. At that time, approximately 17 brands containing meropenem were already available in Russia. Another recent addition is Folicinate (calcium folinate) from Pharmasynthesis, aimed at reducing chemotherapy toxicity. Pharmasynthesis became the seventh manufacturer of this drug in Russia.
Sanofi introduced MenQuadfi, a vaccine for the prevention of meningococcal infection in children from 6 weeks of age. This complements their earlier supply of Menactra, which is intended for children from 9 months old.
The total number of INNs on the Russian market increased by 13 positions over the year, reaching 1,900. Notably, tirzepatide—a drug similar to Eli Lilly’s Munjaro—was among the new INNs. Munjaro is not registered in Russia. The Ministry of Health approved two domestic analogues in 2025: Tirzetta (Promomed) and Sejaro (Geropharm). These entered the market within a month of registration.
Additional INNs introduced include loxoprofen, an NSAID launched by Russia’s Loxon and india’s Dr. Reddy’s Laboratories. Although registered in 2024, loxoprofen products appeared in pharmacies only in May–June 2025.
Also in 2025, drugs with josamycin entered the market — Vilpramycin (Promomed) and Josafen (Pharmstandard), Russian generics of the original Vilprafen (Astellas). After the global supply of Vilprafen was halted, domestic manufacturers obtained registration certificates in 2024 to localize production.
Earlier reports from RNC Pharma indicated that drug production in Russia in January–May 2025 amounted to 396.9 billion rubles, a 19.7% growth y-o-y.
